News

The new combined company, known as NeuroBo Pharmaceuticals began trading on the Nasdaq exchange under the ticker “NRBO” on December 31, 2019. NeuroBo will focus on advancing the

Based in Menlo Park of California, Dermira is involved in the development of novel therapies to treat patients with chronic skin conditions. As per terms of the deal,

These investigational agents have potential for use in HIV long-acting therapies for treatment and prevention, as well as cure strategies. HIV bNAbs are a class of immunotherapy agents

The Phase 3 study, which enrolled 2,838 adults, age 18-45 years, met both the primary and secondary endpoints. “We are thrilled with the results of the CONSTANT study,

Under the three-year collaboration, Empirico will use its Precision Insights Platform to determine therapeutic targets for indications and tissues, which are responsive to antisense technology. The Precision Insights

This exploratory Phase 2 trial, which is subject to the receipt of adequate funding, is designed to assess safety, pharmacokinetics and exploratory measures of function including cardiac, skeletal

The technology is expected to be capable of enumerating, screening, and scoring billions of synthetically feasible, virtual compounds supporting the identification and optimization of potential new therapeutic candidates.

Keytruda has been approved to treat patients with BCG- unresponsive, high-risk NMIBC with carcinoma in situ (CIS) with or without papillary tumours who are ineligible for or have

SM-88 is one of the cancer metabolism-based therapies (CMBTs) that are being developed by Tyme Technologies. According to the company, CMBTs are investigational compounds that can potentially disrupt